GBL Antibody
| Code | Size | Price |
|---|
| PSI-3495-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-3495-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
GBL Antibody: GBL, LST8, POP3, WAT1, GbetaL, GBL, Target of rapamycin complex subunit LST8, G protein beta subunit-like, TORC subunit LST8
Application Note:
GbL antibody can be used for the detection of GbL by Western blot at 1 and 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 10 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
GBL Antibody: GbetaL (G protein beta protein subunit-like) is a member of a signaling pathway that regulates mammalian cell growth in response to the presence of nutrients and growth factors. It binds to the kinase domain of TOR (Target of rapamycin, also known as mTOR), an evolutionarily conserved serine/threonine kinase that regulates cell growth and cell cycle through its ability to integrate signals from nutrient levels and growth factors. Rapamycin inhibits TOR resulting in reduced cell growth and reduced rates of cell cycle and cell proliferation. TOR is normally associated with GbetaL and an additional regulatory protein RAPTOR, allowing TOR to control protein biosynthesis. The binding of GbetaL to TOR stimulates TOR's kinase activity towards downstream proteins such as RPS6K (ribosomal protein S6 kinase) and the translation factor 4E-BP1 which leads to increased protein translation and cell growth.
Background References:
- Kim D-H, Sarbassov DD, Ali SM, et al. GβL, a positive regulator of the Rapamycin-sensitive pathway required for the nutrient-sensitive interaction between Raptor and mTOR. Mol. Cell 2003; 11:895-904.
- Shamji AF, Ngheim P, and Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell 2003; 12:271-80.
- Fingar DC and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71.
Buffer:
GBL Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
GbL antibody was raised against a 14 amino acid synthetic peptide from near the carboxy terminus of human GbL.
The immunogen is located within the first 50 amino acids of GBL.
The immunogen is located within the first 50 amino acids of GBL.
NCBI Gene ID #:
64223
NCBI Official Name:
G protein beta subunit-like
NCBI Official Symbol:
MLST8
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAH52292
Protein GI Number:
30411038
Purification:
GBL Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
Q9BVC4
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | GbL Peptide | PSI-3495P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|